Acadia Pharmaceuticals (ACAD) Capital Expenditures (2012 - 2026)

Acadia Pharmaceuticals' Capital Expenditures history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $9.9 million (up 1793.31% YoY), while the FY2025 annual figure was $4.7 million, up 796.75% from the prior year.
• Capital Expenditures for Q1 2026 stood at $5.2 million, up from $4.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $5.2 million in Q1 2026, with the low at $70000.0 in Q3 2024.
• The 3-year median for Capital Expenditures is $420500.0 (2024), against an average of $1.7 million.
• Peak annual rise in Capital Expenditures reached 784.11% in 2025, while the deepest fall reached 454.29% in 2025.
• Acadia Pharmaceuticals' Capital Expenditures stood at $453000.0 in 2024, then surged by 784.11% to $4.0 million in 2025, then surged by 30.14% to $5.2 million in 2026.
• Business Quant data shows ACAD's Capital Expenditures at $5.2 million in Q1 2026, $4.0 million in Q4 2025, and $388000.0 in Q3 2025.